Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Arcus Biosciences stock
Own Arcus Biosciences stock in just a few minutes.
Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 236 staff and has a trailing 12-month revenue of around USD$77.5 million.
How to buy shares in Arcus Biosciences
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Arcus Biosciences. Find the stock by name or ticker symbol: RCUS. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arcus Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arcus Biosciences, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Arcus Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Arcus Biosciences share price
Use our graph to track the performance of RCUS stocks over time.Arcus Biosciences shares at a glance
Information last updated 2021-04-09.
| 52-week range | USD$15.03 - USD$42.36 |
|---|---|
| 50-day moving average | USD$33.5491 |
| 200-day moving average | USD$28.7477 |
| Wall St. target price | USD$53.2 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.589 |
Buy Arcus Biosciences shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arcus Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arcus Biosciences financials
| Revenue TTM | USD$77.5 million |
|---|---|
| Gross profit TTM | USD$-81,831,000 |
| Return on assets TTM | -15.92% |
| Return on equity TTM | -36.89% |
| Profit margin | -158.49% |
| Book value | $7.714 |
| Market capitalisation | USD$2.2 billion |
TTM: trailing 12 months
Shorting Arcus Biosciences shares
There are currently 5.9 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 0.1% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.
Arcus Biosciences's "short interest ratio" (SIR)
Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 576566.53620352). Arcus Biosciences's SIR currently stands at 10.22. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 10220 shares are currently held short.
However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 80 shares are currently held short) or 0.1025% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 103 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcus Biosciences.
Find out more about how you can short Arcus Biosciences stock.
Arcus Biosciences share dividends
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Arcus Biosciences share price volatility
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $15.03 up to $42.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.0771. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arcus Biosciences overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert